Emerging Challenges in Managing Hepatitis B in HIV Patients

[1]  V. Soriano,et al.  Tenofovir for Hepatitis Delta , 2016, Hepatology.

[2]  C. Delaugerre,et al.  Low Risk of Lamivudine-Resistant HBV and Hepatic Fares in Treated HIV–HBV-Coinfected Patients from Côte d'Ivoire , 2015, Antiviral therapy.

[3]  M. Raza,et al.  First report of successful clearance of hepatitis B and D coinfection with tenofovir monotherapy , 2015, Hepatology.

[4]  S. Chakrabarti,et al.  High Incidence of Lamivudine-Resistance-Associated Vaccine-Escape HBV Mutants among HIV-Coinfected Patients on Prolonged Antiretroviral Therapy , 2015, Antiviral therapy.

[5]  F. Anania,et al.  Hepatitis B Virus Reactivation During Successful Treatment of Hepatitis C Virus With Sofosbuvir and Simeprevir. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  A. Lok,et al.  Preventing hepatitis B reactivation due to immunosuppressive drug treatments. , 2015, JAMA.

[7]  F. Zoulim,et al.  Antiviral therapies and prospects for a cure of chronic hepatitis B. , 2015, Cold Spring Harbor perspectives in medicine.

[8]  M. Yuen,et al.  O009 : A prospective study of hepatitis B reactivation in patients with prior HBV exposure undergoing hematopoietic stem cell transplantation: Reactivation association with graft-versus-host disease , 2015 .

[9]  A. Lok,et al.  Strategies to control hepatitis B: Public policy, epidemiology, vaccine and drugs. , 2015, Journal of hepatology.

[10]  R. Idilman,et al.  O118 : Optimizing the prenylation inhibitor lonafarnib using ritonavir boosting in patients with chronic delta hepatitis , 2015 .

[11]  N. Semmo,et al.  O010 : T and B cell responses and previous exposure to hepatitis B virus in “anti-HBC alone” patients , 2015 .

[12]  T. Berg,et al.  O119 : Stopping tenofovir disoproxil fumarate (TDF) treatment after long term virologic suppression in HBeAg-negative CHB: Week 48 interim results from an ongoing randomized, controlled trial (“finite CHB”) , 2015 .

[13]  J. Pérez-Calle,et al.  Hepatitis B and immunosuppressive therapies for chronic inflammatory diseases: When and how to apply prophylaxis, with a special focus on corticosteroid therapy. , 2015, World journal of hepatology.

[14]  A. Lok.  Personalized treatment of hepatitis B , 2015, Clinical and molecular hepatology.

[15]  M. Buti,et al.  Seven-Year Efficacy and Safety of Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Virus Infection , 2014, Digestive Diseases and Sciences.

[16]  A. Lok,et al.  Hepatitis B virus infection , 2014, The Lancet.

[17]  K. Kitrinos,et al.  No resistance to tenofovir disoproxil fumarate through 96 weeks of treatment in patients with lamivudine-resistant chronic hepatitis B. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[18]  K. Kitrinos,et al.  Evaluation of HBV DNA decay kinetics in patients containing both rtM204V/I mutant and wild‐type HBV subpopulations during tenofovir DF (TDF) monotherapy or combination therapy with emtricitabine (FTC)/TDF , 2014, Journal of medical virology.

[19]  V. Soriano,et al.  Management and treatment of chronic hepatitis B in HIV-positive patients , 2014, Annals of medicine.

[20]  C. Delaugerre,et al.  Persistent viremia in human immunodeficiency virus/hepatitis B coinfected patients undergoing long‐term tenofovir: Virological and clinical implications , 2014, Hepatology.

[21]  Jaw-Town Lin,et al.  Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study. , 2014, Gastroenterology.

[22]  V. Soriano,et al.  Hepatitis delta is a major determinant of liver decompensation events and death in HIV-infected patients. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  M. Fälth,et al.  Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. , 2014, Gastroenterology.

[24]  C. Yurdaydın,et al.  O4 PROLONGED THERAPY OF HEPATITIS DELTA FOR 96 WEEKS WITH PEGYLATED-INTERFERON-α-2a PLUS TENOFOVIR OR PLACEBO DOES NOT PREVENT HDVRNA RELAPSE AFTER TREATMENT: THE HIDIT-2 STUDY , 2014 .

[25]  A. Horban,et al.  Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B. , 2014, Gastroenterology.

[26]  R. Piso.  Can we trust the guidelines? Comparison between the data presented and the recommendations of the International Antiviral Society-USA Panel. , 2014, Journal of the International AIDS Society.

[27]  Xinwen Chen,et al.  Spontaneous reactivation of hepatitis B virus replication in an HIV coinfected patient with isolated anti-Hepatitis B core antibodies , 2014, Virology Journal.

[28]  D. Cattaneo,et al.  Recurrence of another hepatitis B virus escape mutant comes back in a patient infected with HIV and low CD4+ count , 2014, Journal of medical virology.

[29]  B. McMahon,et al.  Strategic use of lamivudine in the management of chronic hepatitis B. , 2013, Antiviral research.

[30]  E. Poveda,et al.  Influence of HIV infection on response to tenofovir in patients with chronic hepatitis B , 2013, AIDS.

[31]  R. Pathapati,et al.  Safety and Efficacy of Hepatitis B Vaccination in Cirrhosis of Liver , 2013, Advances in virology.

[32]  J. Koskinas,et al.  Hepatitis B virus reactivation during therapy with ustekinumab for psoriasis in a hepatitis B surface‐antigen‐negative anti‐HBs‐positive patient , 2013, The British journal of dermatology.

[33]  M. Kew.  Hepatitis viruses (other than hepatitis B and C viruses) as causes of hepatocellular carcinoma: an update , 2013, Journal of viral hepatitis.

[34]  C. Thio,et al.  Predictors of the isolated hepatitis B core antibody pattern in HIV-infected and -uninfected men in the multicenter AIDS cohort study. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[35]  M. Mulligan,et al.  Strategies to increase responsiveness to hepatitis B vaccination in adults with HIV-1. , 2012, The Lancet. Infectious diseases.

[36]  D. Samuel,et al.  Liver Transplantation in Delta Virus Infection , 2012, Seminars in Liver Disease.

[37]  V. Soriano,et al.  Management of hepatitis C in HIV and/or HBV co-infected patients. , 2012, Best practice & research. Clinical gastroenterology.

[38]  C. Yurdaydın.  Treatment of Chronic Delta Hepatitis , 2012, Seminars in Liver Disease.

[39]  P. Farci,et al.  Clinical Features of Hepatitis D , 2012, Seminars in Liver Disease.

[40]  J. Casado,et al.  Proximal tubular renal dysfunction or damage in HIV-infected patients. , 2012, AIDS reviews.

[41]  M. Manns,et al.  Hepatitis Delta and HIV Infection , 2012, Seminars in Liver Disease.

[42]  P. Tebas,et al.  Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents , 2012, AIDS.

[43]  E. Delaporte,et al.  Lamivudine-Resistant HBV Infection in HIV-Positive Patients Receiving Antiretroviral Therapy in a Public Routine Clinic in Cameroon , 2012, Antiviral therapy.

[44]  M. Winters,et al.  HIV-HBV vaccine escape mutant infection with loss of HBV surface antibody and persistent HBV viremia on tenofovir/emtricitabine without antiviral resistance. , 2011, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[45]  C. Leen,et al.  Hepatitis delta in HIV-infected individuals in Europe , 2011, AIDS.

[46]  C. Tural,et al.  HBV Primary Drug Resistance in Newly Diagnosed HIV–Hbv-Coinfected Individuals in Spain , 2011, Antiviral therapy.

[47]  F. Carrat,et al.  Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: a randomized controlled trial. , 2011, JAMA.

[48]  A. Tamori,et al.  Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts , 2011, Journal of Gastroenterology.

[49]  E. Poveda,et al.  Clinical and virological outcomes in HIV-infected patients with chronic hepatitis B on long-term nucleos(t)ide analogues , 2011, AIDS.

[50]  F. Sarfo,et al.  Detection of Highly Prevalent Hepatitis B Virus Coinfection among HIV-Seropositive Persons in Ghana , 2010, Journal of Clinical Microbiology.

[51]  A. Mocroft,et al.  Frequent hepatitis B virus rebound among HIV–hepatitis B virus-coinfected patients following antiretroviral therapy interruption , 2010, AIDS.

[52]  H. Te,et al.  Epidemiology of hepatitis B and C viruses: a global overview. , 2010, Clinics in liver disease.

[53]  K. H. Hullsiek,et al.  Epidemiology of Hepatitis B virus infection in a US cohort of HIV-infected individuals during the past 20 years. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[54]  B. McMahon,et al.  Chronic hepatitis B: Update 2009 , 2009, Hepatology.

[55]  C. Thio.  Hepatitis B and human immunodeficiency virus coinfection , 2009, Hepatology.

[56]  S. Lewin,et al.  Immunopathogenesis of hepatic flare in HIV/hepatitis B virus (HBV)-coinfected individuals after the initiation of HBV-active antiretroviral therapy. , 2009, The Journal of infectious diseases.

[57]  V. Soriano,et al.  Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir , 2009, AIDS.

[58]  Y. Jeng,et al.  Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. , 2009, Gastroenterology.

[59]  V. Soriano,et al.  Risks and benefits of using antiretroviral therapy in HIV-infected patients with chronic hepatitis B in developing regions. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[60]  R. Chaisson,et al.  Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[61]  N. Probst-Hensch,et al.  Influence of HIV-related immunodeficiency on the risk of hepatocellular carcinoma , 2008, Infectious Agents and Cancer.

[62]  Amalio Telenti,et al.  Antiretroviral Treatment of Adult HIV Infection2010 Recommendations of the International AIDS Society–USA Panel , 2010 .

[63]  V. Soriano,et al.  Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel. , 2008, AIDS.

[64]  Shou-Dong Lee,et al.  Hepatitis B virus/hepatitis C virus coinfection: Epidemiology, clinical features, viral interactions and treatment , 2008, Journal of gastroenterology and hepatology.

[65]  C. Yurdaydın,et al.  Treatment of chronic delta hepatitis with lamivudine vs lamivudine + interferon vs interferon , 2008, Journal of viral hepatitis.

[66]  V. Soriano,et al.  Antiretroviral drugs and liver injury. , 2008, AIDS.

[67]  C. Toro,et al.  Does Treatment of Hepatitis B virus (HBV) Infection Reduce Hepatitis Delta virus (HDV) Replication in HIV-HBV-HDV-Coinfected Patients? , 2008, Antiviral therapy.

[68]  E. Schiff,et al.  Clinical Features of Hepatitis , 2007 .

[69]  G. Dore,et al.  Hepatitis B and C virus coinfection in The TREAT Asia HIV Observational Database , 2007, Journal of gastroenterology and hepatology.

[70]  V. Soriano,et al.  Immunizations in HIV-infected adults. , 2007, AIDS reviews.

[71]  Lin Shen,et al.  The HBV drug entecavir - effects on HIV-1 replication and resistance. , 2007, The New England journal of medicine.

[72]  M. Manns,et al.  Hepatitis D virus infection—Not a vanishing disease in Europe! , 2007, Hepatology.

[73]  V. Soriano,et al.  Treatment of chronic hepatitis B or C in HIV-infected patients with dual viral hepatitis. , 2007, The Journal of infectious diseases.

[74]  P. Farci.  Treatment of chronic hepatitis D: New advances, old challenges , 2006, Hepatology.

[75]  A. Andriulli,et al.  Pegylated interferon alpha‐2b as monotherapy or in combination with ribavirin in chronic hepatitis delta , 2006, Hepatology.

[76]  D. Häussinger,et al.  Treatment of chronic hepatitis delta with pegylated interferon‐α2b , 2006 .

[77]  W. Yeo,et al.  Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy , 2006, Hepatology.

[78]  Guan-Tarn Huang,et al.  Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. , 2006, JAMA.

[79]  A. Mocroft,et al.  Is there evidence for an increase in the death rate from liver-related disease in patients with HIV? , 2005, AIDS.

[80]  F. Tacke,et al.  Selection of Hepatitis B Virus Polymerase Mutations in HIV-Coinfected Patients Treated with Tenofovir , 2005, Antiviral therapy.

[81]  P. Sax,et al.  Response to hepatitis B vaccine in HIV-1-positive subjects who test positive for isolated antibody to hepatitis B core antigen: implications for hepatitis B vaccine strategies. , 2005, The Journal of infectious diseases.

[82]  A. Barone,et al.  Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose. , 2005, Vaccine.

[83]  A. Mocroft,et al.  Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort , 2005, AIDS.

[84]  M. Perazella,et al.  Tenofovir-associated nephrotoxicity: Fanconi syndrome and renal failure. , 2004, The American journal of medicine.

[85]  R. Purcell,et al.  Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. , 2004, Gastroenterology.

[86]  V. Soriano,et al.  Tenofovir-related nephrotoxicity in HIV-infected patients. , 2004, AIDS.

[87]  A. McNaghten,et al.  Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects. , 2003, The Journal of infectious diseases.

[88]  D. Droz,et al.  Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[89]  Y. Jeng,et al.  Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients , 2003, Hepatology.

[90]  J. Phair,et al.  HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS) , 2002, The Lancet.

[91]  M. Manns,et al.  Peginterferon alfa-2b plus ribavirin for chronic hepatitis , 2002, The Lancet.

[92]  H. Agut,et al.  Primary infection with a lamivudine-resistant hepatitis B virus. , 2002, AIDS.

[93]  M. Velasco,et al.  Resolution of chronic hepatitis B after ritonavir treatment in an HIV-infected patient. , 1999, The New England journal of medicine.

[94]  G. Fattovich,et al.  Clinical and virological profiles in patients with multiple hepatitis virus infections. , 1993, Gastroenterology.

[95]  Hepatitis B vaccines: WHO position paper – July 2017. , 2017, Releve epidemiologique hebdomadaire.

[96]  Y. Shin,et al.  Retraction notice to: Clinical significance of the best response during repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma [J. Hepatol. 2014;60:1212–1218]. , 2015, Journal of hepatology.

[97]  Jennifer F Hoy,et al.  Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. , 2014, JAMA.

[98]  M. Demir,et al.  Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[99]  D. Harnois.  Peginterferon plus Adefovir versus Either Drug Alone for Hepatitis Delta , 2011 .

[100]  P. Calès,et al.  Resolution of chronic hepatitis Delta after 1 year of combined therapy with pegylated interferon, tenofovir and emtricitabine. , 2010, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[101]  Norman Gitlin,et al.  Chronic hepatitis B : an update , 2010 .

[102]  Douglas D. Richman,et al.  Antiretroviral Treatment of Adult HIV Infection , 2008 .

[103]  J. Feld,et al.  Viral hepatitis and HIV in Africa. , 2007, AIDS reviews.

[104]  M. Kane.  Global programme for control of hepatitis B infection. , 1995, Vaccine.

[105]  J. Wands,et al.  Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. , 1975, Gastroenterology.